Arcutis Biotherapeutics (ARQT) said Sunday its preliminary fiscal Q4 revenue is expected to increase by about 366% to $63 million, driven by the demand for Zoryve, a skin disease treatment.
Analysts surveyed by FactSet expect revenue of $56.5 million.
Meanwhile, full-year product revenue is expected to be about $160 million, up by about 449% from a year earlier.
As of Dec. 31, preliminary cash, cash equivalents, restricted cash and marketable securities are expected to be about $229 million.
The company is set to report its fiscal Q4 results on Feb. 25.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。